Clinical importance of DNA repair inhibitors in cancer therapy

Memo - Magazine of European Medical Oncology

Volumn 2, Issue 1, 2009, Pages 9-14

  Hosoya, N ^a   Miyagawa, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

BRCA defective tumours; Cancer therapy; DNA repair inhibitors; PARP inhibitors; Targeted therapy

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 6 O BENZYLGUANINE; 7 HYDROXYSTAUROSPORINE; AG 014699; AG014699; ANTINEOPLASTIC AGENT; AZD 2281; BEVACIZUMAB; BSI 201; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DNA REPAIR INHIBITOR; DOXORUBICIN; FLUDARABINE; GEMCITABINE; INO 1001; IRINOTECAN; KU 0059436; PACLITAXEL; PERIFOSINE; PREDNISONE; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 844; XL844;

ACUTE LEUKEMIA; ADVANCED CANCER; ASTROCYTOMA; BRAIN STEM TUMOR; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; ENZYME INACTIVATION; EXCISION REPAIR; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HOMOLOGOUS RECOMBINATION; HUMAN; KIDNEY CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOMA; LYMPHOMA; LYMPHOMA CELL; MELANOMA; METASTASIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGODENDROGLIOMA; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; T CELL LYMPHOMA; UTERINE CARCINOSARCOMA;

EID: 77953411882     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-008-0081-7     Document Type: Review

References (36)

1. KK Khanna SP Jackson 2001 DNA double-strand breaks: signaling, repair and the cancer connection Nat Genet 27 247 254 (Pubitemid 32201842)
2. DC van Gent JH Hoeijmakers R Kanaar 2001 Chromosomal stability and the DNA double-stranded break connection Nat Rev Genet 2 196 206 (Pubitemid 33674018)
3. T Helleday E Petermann C Lundin 2008 DNA repair pathways as targets for cancer therapy Nat Rev Cancer 8 193 204 (Pubitemid 351301852)
4. SA Martin CJ Lord A Ashworth 2008 DNA repair deficiency as a therapeutic target in cancer Curr Opin Genet Dev 18 80 86 (Pubitemid 351694447)
5. T Helleday J Lo DC van Gent BP Engelward 2007 DNA double-strand break repair: from mechanistic understanding to cancer treatment DNA Repair 6 923 935 (Pubitemid 46880473)
6. P Sung H Klein 2006 Mechanism of homologous recombination: mediators and helicases take on regulatory functions Nat Rev Mol Cell Biol 7 739 750 (Pubitemid 44450458)
7. RA Sharma GL Dianov 2007 Targeting base excision repair to improve cancer therapies Mol Aspects Med 28 345 374 (Pubitemid 47331614)
8. K Sugasawa T Okamoto Y Shimizu 2001 A multistep damage recognition mechanism for global genomic nucleotide excision repair Genes Dev 15 507 521 (Pubitemid 32205141)
9. T Lindahl B Demple P Robins 1982 Suicide inactivation of the E. coli O6-methylguanine-DNA methyltransferase EMBO J 1 1359 1363
10. MLG Dronkert R Kanaar 2001 Repair of DNA interstrand cross-links Mutat Res 486 217 247 (Pubitemid 32763210)
11. Y Pommier 2006 Topoisomerase I inhibitors: camptothecins and beyond Nature Rev Cancer 6 789 802 (Pubitemid 44450467)
12. C Arnaudeau C Lundin T Helleday 2001 DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells J Mol Biol 307 1235 1245 (Pubitemid 33027636)
13. KJ Patel H Joenje 2007 Fanconi anemia and DNA replication repair DNA Repair (Amst) 6 885 890 (Pubitemid 46880469)
14. K Hanada M Budzowska SL Davies 2007 The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks Nat Struct Mol Biol 14 1096 1104 (Pubitemid 350060335)
15. L Wu ID Hickson 2006 DNA helicases required for homologous recombination and repair of damaged replication forks Annu Rev Genet 40 279 306 (Pubitemid 44956787)
16. MR Middleton GP Margison 2003 Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway Lancet Oncol 4 37 44 (Pubitemid 36124189)
17. BW Durkacz O Omidiji DA Gray 1980 (ADP-ribose)n participates in DNA excision repair Nature 283 593 596 (Pubitemid 10136042)
18. JM de Murcia C Niedergang C Trucco 1997 Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci USA 94 7303 7307 (Pubitemid 27345310)
19. N Schultz E Lopez N Saleh-Gohari 2003 Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination Nucleic Acids Res 31 4959 4964 (Pubitemid 37441861)
20. K Ratnam JA Low 2007 Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology Clin Cancer Res 13 1383 1388 (Pubitemid 46450426)
21. CK Donawho Y Luo Y Luo 2007 ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2728 2737 (Pubitemid 46795129)
22. S Adimoolam M Sirisawad J Chen 2007 HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination Proc Natl Acad Sci USA 104 19482 19487
23. IH Ismail S Martensson D Moshinsky 2004 SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization Oncogene 23 873 882 (Pubitemid 38250932)
24. Y Zhao HD Thomas MA Batey 2006 Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 Cancer Res 66 5354 5362 (Pubitemid 43844961)
25. R Marone V Cmiljanovic B Giese 2007 Targeting phosphoinositide 3-kinase: moving towards therapy Biochim Biophys Acta 1784 159 185
26. M Ranson MR Middleton J Bridgewater 2006 Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors Clin Cancer Res 12 1577 1584
27. M Ranson P Hersey D Thompson 2007 Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma J Clin Oncol 25 2540 2545 (Pubitemid 47041227)
28. OA Khan M Ranson M Michael 2008 A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer Br J Cancer 98 1614 1618 (Pubitemid 351684692)
29. PN Lara Jr PC Mack T Synold 2005 The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial Clin Cancer Res 11 4444 4450 (Pubitemid 40825635)
30. SJ Hotte A Oza EW Winquist 2006 Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study Ann Oncol 17 334 340 (Pubitemid 43160126)
31. I Hickson Y Zhao CJ Richardson 2004 Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM Cancer Res 64 9152 9159 (Pubitemid 39665530)
32. H Farmer N McCabe CJ Lord 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917 921 (Pubitemid 40559006)
33. HE Bryant N Schultz HD Thomas 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913 917 (Pubitemid 40559005)
34. W Sakai EM Swisher BY Karlan 2008 Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 28 1116 1120 (Pubitemid 351317449)
35. SL Edwards R Brough CJ Lord 2008 Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 1111 1115 (Pubitemid 351317441)
36. EM Swisher W Sakai BY Karlan 2008 Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res 68 2581 2586 (Pubitemid 351556255)